相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
J. Tabernero et al.
ANNALS OF ONCOLOGY (2018)
Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
Takayuki Yoshino et al.
EUROPEAN JOURNAL OF CANCER (2017)
The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
Chang Jiang et al.
JOURNAL OF CANCER (2017)
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Charles S. Fuchs et al.
JOURNAL OF GASTRIC CANCER (2017)
Safety and efficacy profile of ramucirumab alone or combined with paclitaxel in metastatic gastric cancer (MGC): A real-life overview of compassionate-use named patients (pts) (RAMoss study)
M. Di Bartolomeo et al.
ANNALS OF ONCOLOGY (2016)
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Charles S. Fuchs et al.
BRITISH JOURNAL OF CANCER (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Unmet needs and challenges in gastric cancer: The way forward
Florian Lordick et al.
CANCER TREATMENT REVIEWS (2014)
Perforation in colorectal stenting: a meta-analysis and a search for risk factors
Emo E. van Halsema et al.
GASTROINTESTINAL ENDOSCOPY (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
Shuichi Hironaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Farbod Shojaei
CANCER LETTERS (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2012)
Screening for gastric cancer in Asia: current evidence and practice
Wai K. Leung et al.
LANCET ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Vascular endothelial growth factor-D and its receptor VEGFR-3:: Two novel independent prognostic markers in gastric adenocarcinoma
S Jüttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
